

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Reproductive Endocrinology Diseases: Hormone Replacement and Therapy for Peri/Menopause

Zoe Roup¹, Greta Wozniak², Konstantinos Tsipras³
and Penelope Sotiropoulou⁴

¹*European University, Nicosia,*

²*Medical School, University of Thessaly, Larissa,*

³*Endocrinology Primary Health Care Center, Athens*

⁴*Technological Education Institute of Athens,*

¹*Cyprus*

^{2,3,4}*Greece*

1. Introduction

There are many female causes for infertility but the incidence of infertility increases with advancing age. Colombat de L'Isere in a chapter on 'Change of Life' in his "Treatise on the diseases and special hygiene of females" (1845) stated: Compelled to yield to the power of time, women now cease to exist for the species, and hence forward live only for themselves" (Colombat de L'Isere M., 1945). Fortunately, this pessimistic outlook on life after menopause has become outdated. Aiming to standardize terminology The World Health Organization (WHO) assembled in 1996 and the Council of Affiliated Menopause Societies (CAMS) in 1999 (WHO Scientific Group: Research on Menopause in the 1990s, Utian WH, 1999). Commonly accepted terms, including pre-menopause, peri-menopause, menopausal transition, and climacteric, were thought to be too vague to be useful. In July of 2001, the Stages of Reproductive Aging Workshop (STRAW) was held to address the absence of a relevant staging system for female reproductive aging, and to discuss the confusing current nomenclature for the pre-menopause (Soules MR, et al., 2001).

The average age of menopause is 51 and less than 1% of women experience it before the age of 40. Some women undergo premature menopause at a very early age affecting their ability to have children. As more and more women delay child bearing, this life altering condition has become more prevalent. Population aging must be added to population growth as very important social problems. Women in our society get married and have children later in life. Therefore, evaluation of ovarian reserve is critical to understanding a patient's reproductive potential.

Ovulatory disorders are a common cause of infertility. Ovulation is controlled by complex interactions between numerous endocrine hormones including FSH, LH, estradiol, progesterone and others. Menopause is the cessation of the primary functions of the human ovaries, with associated changes in pituitary gonadotropin secretion occurring secondary to

the decline in ovarian sex steroid and protein production. However, increasing evidence suggests that aging is associated with dynamic changes in the hypothalamic and pituitary components of the reproductive axis that are independent of changes in gonadal hormone secretion (Hall JE, et al., 2000). Imbalances in these hormones, or alterations in the “feedback mechanism”, can prevent ovulation, or cause it to be irregular.

2. Epidemiology of menopause

Most estimates of age at natural menopause are based on samples of Caucasian women in Western societies. In one large, comprehensive, prospective cohort study of mid-aged, Caucasian U.S. women (the Massachusetts Women's Health Study [MWHS]) the age at natural menopause occurred at 51.3 years, (Gold EB, et al., 2001) confirming prior reports. The Study of Women's Health Across the Nation (SWAN), a multicenter, multiethnic, community-based cohort study of women and the menopausal transition, reported the overall median age at natural menopause to be 51.4 years, after adjustment for other factors (Gold EB, et al., 2001). Studies performed outside the United States suggest that Africans, African Americans, (Bromberger JT, et al., 1997) and Hispanics of Mexican descent experience menopause at an earlier age than Caucasian women, as opposed to Japanese (Tamada T & Iwasake H., 1995) and Malaysian (Ismael NN., 1994) women, who report a similar median age of menopause to women of European descent.

Lower educational attainment and unemployment have been independently associated with earlier age at menopause (Gold EB, et al., 2001; Cramer DW, 1994 et al) and may be markers for elevated bio-psychosocial stress. Women who are separated, divorced, or widowed have been shown to have an earlier menopause than women who are married (Gold EB, et al., 2001). Age at natural menopause for parous women has been reported to occur significantly later than for nulliparous women. (Gold EB, et al., 2001; Anasti JN., 1998; Tibilleto MG, et al., 1999; Weel AE, , et al., 1999). Gold et al. and Cramer et al. observed a trend of increasing age at menopause with increasing number of life births, and that prior use of oral contraceptives was associated with earlier age at natural menopause however, a slight prolongation of the reproductive life-span has been associated with oral contraceptive use (Cramer DW, et al., 1994).

The proposed mechanism by which parity and use of oral contraceptives may result in later age at natural menopause involves reducing ovulatory cycles earlier in life and thus preserving oocytes longer, resulting in later menopause (Gold EB, et al., 2001). Some studies show that women with a lower body mass index (BMI) experience an earlier menopause; other studies have not confirmed this finding (Zapantis G & Santoro N., 2002). Environmental toxicants may play a role in early menopause. A large body of literature shows that current smokers tend to experience menopause at an earlier age (1 to 2 years) than non-smokers (Reynaud K., et al, 2001, Hreinsson JG, et al., 2002, Loffler KA, et al., 2003, Burger HG, et al., 2002) and may have a shorter menopausal transition (Gold EB, 2001, et al).

It has been shown that polycyclic hydrocarbons in cigarette smoke are toxic to ovarian follicles and may lead to their loss and thus an earlier menopause in smokers. Harlow et al. observed that women with a history of medically treated depression had a 20% increased rate of entering peri-menopause sooner than women with no depression history, after adjustment for age, parity, age at menarche, education, cigarette smoking, and BMI. Epidemiology gives answers about populations, whereas clinical medicine deals with

patient samples and individuals. For example, in population-based studies, (Gold EB, et al., 2001) no global increased prevalence of depression has been associated with the menopause transition, whereas in clinical samples, depression around menopause has reportedly increased. Furthermore, symptoms vary among women, and the distinction between populations versus individuals must be made when one is evaluating epidemiologic factors related to menopause.

3. Menopause pathogenesis

The basis of reproductive senescence in women is oocyte/follicle depletion in the ovary. Developmentally, a woman attains her peak oocyte complement at 20 weeks' gestational age. Between 20 and 40 weeks' gestation, two thirds of a woman's oocyte complement is lost, and total oocyte counts drop from a mean of about 6 to 8 million to 1 to 2 million (Zapantis G & Santoro N., 2002).

The most massive wave of atresia (rate of follicle loss) that a woman ever experiences happens before she is born. At the onset of puberty, germ cell mass has been reduced to 300,000 to 500,000 units. Subsequent reproductive aging consists of a steady loss of oocytes through atresia or ovulation and does not necessarily occur at a constant rate. Atresia is an apoptotic process. During the 35 to 40 years of reproductive life, 400 to 500 oocytes will be selected for ovulation. By menopause, only a few hundred follicles remain (Speroff L, et al., 1999).

The relatively wide age range (42 to 58 years) for menopause in normal women seems to indicate that women may be endowed with a highly variable number of oocytes, or that the rate of oocyte loss varies greatly (Soules MR, et al., 2001). Concurrent with the loss of ovarian follicles as a woman transitions to menopause are hormonal changes in the hypothalamic-pituitary-ovarian axis. Follicle-stimulating hormone (FSH) is an established indirect marker of follicular activity; as follicle numbers decline, FSH levels increase (Burger HG, et al., 2002). An elevated level is often the first clinically measurable sign of reproductive aging. Large cross-sectional studies have reported a progressive, quantitative rise in FSH with age (Ahmed-Ebbiary NA, et al., 1994). In the late reproductive years, initial elevations in FSH are most prominent in the early follicular phase of the menstrual cycle but are intermittent and do not occur in every cycle (Klein NA, Soules MR., 1998). This increase is first detectable some years before any clinical indications of approaching menopause are evident (Burger HG, et al., 2002).

The rise in FSH appears to be the result of a decline in inhibin -B, a dimeric protein that reflects the fall in ovarian follicle numbers. Is a small pleomorphic peptide made within the ovarian granulosa and luteinized granulosa cells, which, although assay specificity and sensitivity in ovarian physiology (Burger HG 1993). Inhibin may be an intraovarian regulator although other peptides such as activin and follistatin are more likely paracrine factors (Findlay JK, et al., 1990) but one of its more important functions appears to be feedback suppression of FSH production (Seifer DB, et al., 1996). In reproductive life, inhibin serves to selectively inhibit FSH by binding to receptors on the anterior pituitary (Robertson DM & Burger HG., 2002). Estradiol is stable or even elevated during the earlier menopause transition; closer to the final menstrual period, a decline is clearly observed (Longscope C, et al., 1986).

Findings from the Melbourne Women's Midlife Health Project, a cohort of women followed through the menopause transition, confirm that a decline in inhibin B precedes the increase in FSH and the decline in estradiol that occur later in the transition (Burger HG, et al., 2007).

The remaining follicles are less likely to function normally, which may lead to erratic follicular development and dysregulation of folliculogenesis (Whiteman MK, et al., 2003, Schwingl PJ, et al., 1994). Although FSH and estradiol vary near menopause, steroidogenic enzymes appear to be completely absent in the postmenopausal ovary after all functional follicles are lost (Couzinet B, et al., 2001). Between the ages of 20 and 40 years, concentrations of total testosterone have been reported to fall by about 50% (Zumoff B, et al., 1995). This age-related decline does not change further during the transition years (Burger HG, et al., 2000). Similarly, dehydroepiandrosterone (DHEA) and its sulphate, DHEAS, decline with age (Rossmanith W et al., 1991., Santoro N, et al., 1998). Because circulating sex hormone-binding globulin (SHBG) decreases across the menopausal transition, free androgen levels actually rise, as indicated by a small increase in free androgen index ($T \div SHBG \times 100$) (Burger HG, et al., 2000). Androstenedione, which remains relatively stable during the transition, is converted to estrone in extra-glandular tissue. This accounts for almost all the estrogen in circulation after menopause.

When ovulation stops, concurrent with a woman's FMP, serum progesterone levels are invariably low (Rannevik G, et al., 1995). Luteinizing hormone (LH) eventually increases, although at a slower rate than FSH. Despite the epidemiologic trend toward elevated FSH and decreased estradiol with progression through the transition, measurement of FSH, inhibin, and estradiol provides at best an unreliable guide to the menopausal status of an individual woman (El-Hage G, et al., 2007; Braunstein GD, et al., 2005). A more rational approach to diagnosing menopause would include an assessment of the longitudinal symptoms of a woman who presents with peri-menopausal complaints (Lobo RA., 1999). Hormone profiles correlate well with symptoms and cycle features (Burger HD, et al., 1995). Thus, if a woman is >45 years old and has had a recent disruption in her menstrual pattern and symptoms suggestive of transient hypo-estrogenemia, it is likely that she has entered her menopausal transition (Santoro N., 2002). That being said, the clinician should take care to rule out other pathologies that can be masked by common complaints associated with the menopausal transition. At minimum, a screening TSH level should be performed, as menstrual irregularity may be the only manifestation of thyroid dysfunction.

4. Regulation of gonadotropins and control of ovarian steroid production

Pituitary gonadotropes synthesize and secrete both LH and FSH. They account for 7% to 15% of anterior pituitary cells. Gonadotropin subunit gene expression is regulated by the frequency of GnRH signal input to pituitary gonadotropes (Haisenleder DJ, et al., 1991). During the menstrual cycle, LH pulse frequency is approximately every 90 minutes in the early follicular phase, 60 to 70 minutes during the late follicular phase, 100 minutes during the early luteal phase, and 200 minutes during the late luteal phase. This variation reflects changes in GnRH pulse frequency, which regulates relative FSH and LH secretion; this, in turn, determines follicle recruitment, development, and ovulation. More rapid GnRH pulse frequencies promote LH secretion, and slower frequencies promote FSH secretion. Although good evidence indicates that changes in GnRH pulse frequency determines differential LH and FSH secretion (Marshall JC, et al., 1993) it is apparent that ovarian steroids and peptide hormones have a major role. Women with hypothalamic stalk section regain their characteristic cycle length when administered an unchanging frequency of exogenous GnRH pulses every 90 minutes.

This indicates that intrinsic rates of follicle development and regression of the corpus luteum, along with their phasing of steroid and peptide hormone production, are major determinants of LH and FSH responses to GnRH. Gonadotropins control the growth and differentiation of the steroid hormone-secreting cells of the ovary, intrinsically linking form and function. A defined sequence of gonadotropin action propels the growth of follicles and the production of steroid hormones. Positive feedback on the pituitary by high concentrations of estrogens leads to the ovulatory surge of LH, which in turn triggers a dramatic differentiation event, resulting in structural reorganization of the pre-ovulatory follicle, release of the ovum, and striking changes in the steroidogenic capacity of the luteinizing cells. Follicular growth, which culminates in ovulation and corpus luteum formation, requires both FSH and LH. Steroidogenic competence of the ovarian follicle is not achieved in the absence of FSH, even if LH is present in abundance. FSH promotes proliferation of the granulosa cells and induces the expression of genes involved in estradiol biosynthesis (Haisenleder DJ, et al., 1991; Kaiser UB, et al., 1997). During the last phase of follicular maturation, when granulosa cells acquire LH receptors, LH is then able to sustain follicular estradiol synthesis. This LH substitution is thought to compensate for the diminished levels of FSH of the late follicular phase consequent to negative-feedback action of estradiol and inhibin. LH action on the granulosa thus rescues the dominant LH-expressing follicle from the fate of atresia. LH stimulation is indispensable for normal ovarian hormone production not only before but also after ovulation. Suppression of LH release leads to a prompt decline in progesterone levels that precede changes in the abundance of mRNAs encoding steroidogenic enzymes or structural changes in the corpus luteum (King JA & Millar RP., 1982).

This acute regulation of ovarian progesterone secretion is controlled by LH via the expression of steroidogenic acute regulatory protein (StAR) messenger RNA (mRNA) and protein, present in both theca-lutein and granulosa-lutein cells throughout the luteal phase are highly expressed in early and midluteal phase, whereas declining StAR mRNA and protein levels are characteristic of late luteal phase. Moreover, StAR protein levels in the corpus luteum are highly correlated with plasma progesterone levels; suppression of LH levels during the midluteal phase markedly decreases plasma progesterone levels and abundance of StAR mRNA transcripts in the corpus luteum (Millar RP, et al., 2004).

4.1 Intra-ovarian control mechanisms

The growth of follicles and the function of the corpus luteum, while under the primary direction of the pituitary, are highly influenced by intra-ovarian factors that modulate the action of gonadotropins. These intra-ovarian factors most likely account for gonadotropin-independent follicular growth, observed differences in the rate and extent of development of ovarian follicles, arrest and initiation of meiosis, dominant follicle selection, and luteolysis. The list of potential paracrine factors that can influence steroid production by theca and granulosa cells is long and diverse. The previous theca cells lacked the aromatase enzyme that is necessary to produce estrogen (Schwanzel-Fukuda M, & Pfaff DW, 1984) so the production of estrogen in granulosa cells indicates presence of aromatase. It includes various growth factors, cytokines, peptide hormones, and steroids such as epidermal growth factor, transforming growth factor β (TGF- β), platelet-derived growth factor, fibroblast growth factors, transforming growth factor α (TGF- α), activins, inhibins, Anti-Müllerian hormone, insulin-like growth factors, estradiol, progesterone, and GnRH (Millar R: 2005; King JA, et al., 2002)

5. The peri-menopausal transition

There is only one marker, menstrual irregularity that can be used to objectively define and establish what is called the peri-menopausal transition. This irregularity will be perceived by patients as skipped menstrual periods or longer durations (about 40 to 60 days) between periods (Harlow SD, et al., 2008). There is no universal pattern; each woman will perceive a change that is her own individual characteristic alteration. Literally means “about or around the menopause.” Generally speaking, the term “menopausal transition” is preferred over peri-menopause and climacteric.

The menopause is that point in time when permanent cessation of menstruation occurs following the loss of ovarian activity. Menopause is derived from the Greek words *men* (month) and *pausis* (cessation). The years prior to menopause that encompass the change from normal ovulatory cycles to cessation of menses are known as the peri-menopausal transitional years, marked by irregularity of menstrual cycles. Climacteric, an older, more general, and less precise term, indicates the period of time when a woman passes from the reproductive stage of life through the peri-menopausal transition and the menopause to the postmenopausal years (Treloar AE, et al., 1967). Menarche is followed by approximately 5–7 years of relatively long cycles at first, and then there is increasing regularity as cycles shorten to reach the usual reproductive age pattern. In the 40s, cycles begin to lengthen again. The highest incidence of anovulatory cycles is under age 20 and over age 40 (Collett ME, et al., 1954). At age 25, over 40% of cycles are between 25 and 28 days in length; from 25 to 35, over 60% are between 25 and 28 days. The perfect 28-day cycle is indeed the most common mode, but it totalled only 12.4% of Vollman’s study cycles. Overall, approximately 15% of reproductive-age cycles are 28 days in length. Only 0.5% of women experience a cycle less than 21 days long, and only 0.9% a cycle greater than 35 days (Munster K, et al., 1992).

Most women have cycles that last from 24 to 35 days, but at least 20% of women experience irregular cycles (Belsey EM & Pinol APY, 1997). When women are in their 40s, anovulation becomes more prevalent, and prior to anovulation, menstrual cycle length increases, beginning 2 to 8 years before menopause (Treloar AE, et al., 1967). Cycles greater than 40 days in length are prevalent in the year before menopause (Ferrell RJ, et al.) The duration of the follicular phase is the major determinant of cycle length (Sherman BM, et al.) This menstrual cycle change prior to menopause is marked by elevated follicle-stimulating hormone (FSH) levels and decreased levels of inhibin, but normal levels of luteinizing hormone (LH) and slightly elevated levels of estradiol (Buckler HM, et al., 1991; MacNaughton J, et al., 1992; Hee J, et al., 1993; Burger HG, et al., 2000,2008). In the average woman, continuing follicular depletion and declining fertility begin at age 37–38, and menopause follows approximately 13 years later (average age 51). However, in epidemiologic studies approximately 10% of women in the general population become menopausal by the age of 45, probably because they were born with a smaller than normal ovarian follicular pool that is functionally depleted at an earlier age. Menopause occurs when the number of remaining follicles falls below a critical threshold, about 1,000, regardless of age (Treloar AE, 1981).

Recent longitudinal studies of women as they pass through the peri-menopausal transition reveal that estrogen levels do not begin a major decline until about a year before menopause. (Burger HG, et al., 2008; Lasley BL, et al., 2002). Indeed, women experiencing the peri-menopausal transition actually have higher overall estrogen levels, a response that

is logically explained by an increased ovarian follicular reaction to the increase in FSH secretion during these years (Santoro N, et al). Variability in estrogen levels is characteristic of the peri-menopausal transition, with greater variability observed in menstrual cycles that display greater irregularity (Meyer PM, et al). As noted, most women experience a 2- to 8-year period of time prior to menopause when anovulation becomes common (Treloar AE, et al., 1996). During this period of time ovarian follicles continue their rate of loss until eventually the supply of follicles is finally depleted (Gougeon A, et al., 1994). The age-related changes in the endocrine characteristics of the menstrual cycle that result from progressive follicular depletion correlate with a measurable decrease in ovarian volume and in the number of antral follicles observed by trans-vaginal ultrasonography during the early follicular phase (Lass A, et al., 1997; Yong PY, et al., 2003; Frattarelli JL, et al., 2000; Dumesic DA, et al., 2001; Bancsi LF, et al., 2002; Kupesic S, et., 2003). The inverse and tight relationship between FSH and inhibin indicates that inhibin is a sensitive marker of ovarian follicular competence and, in turn, that FSH measurement is a clinical assessment of inhibin (MacNaughton J, et al., 1992; Hee J, et al., 1993). The decrease in inhibin secretion by the ovarian follicles begins early (around age 35), but accelerates after 40 years of age. This is reflected in the decrease in fecundity that occurs with aging. The major decrease in estradiol levels began about 2 years before menopause (Sowers MR, et al., 2008). Declining levels of inhibin-B and Anti-Müllerian Hormone (AMH) reached a low to non-detectable point about 5 years before menopause (Sowers MR, et al., 2008).

Although the inhibin-B and AMH results are in general agreement with other reports, the exactness of the timing is limited by the fact that the blood samples were obtained from only 50 women in the study. Nevertheless, the Michigan study confirms the validity of AMH as a marker for the ovarian reserve of follicles. Unlike inhibin-B, AMH is not a participant in the feedback relationship between the ovary and the pituitary gonadotropins, rather AMH, a product of granulosa cells, reflects the number of follicles present in the ovaries awaiting FSH stimulation (Visser JA, et al). The variability in these measurements from individual to individual, however, precludes the practical use of these tests to predict with accuracy the future rate of menopause. The peri-menopausal years are a time period during which postmenopausal levels of FSH (greater than 20 IU/L) can be seen despite continued menstrual bleeding, while LH levels still remain in the normal range. Occasionally, corpus luteum formation and function occur, and the peri-menopausal woman is not safely beyond the risk of an unplanned and unexpected pregnancy until elevated levels of both FSH (>20 IU/L) and LH (>30 IU/L) can be demonstrated. The median age for the onset of this transition was 47.5 years. Only 10% of women ceased menstruating abruptly with no period of prolonged irregularity. The peri-menopausal transition from reproductive to post-reproductive status was, for most women, approximately 4 years in duration. In the study by Treloar, the average age for entry into the peri-menopausal transition was 45.1, and the age range that included 95% of the women was 39–51 (Treloar AE, 1996). The mean duration of the peri-menopausal transition was 5.0 years, with a range of 2 to 8 years.

5.1 Endocrine activity of the peri and post-menopausal ovary

As reviewed above, mean estradiol levels are normal or high in peri-menopausal women, and FSH levels are often not suppressed despite these high estradiol levels. These aspects of pituitary-ovarian relationships are contrary to expected physiology. It is proposed that, decreasing ovarian production of inhibin plays a role in the high average estrogen levels documented during the peri-menopause. More specifically, the B subtype of inhibin, a small

peptide made in ovarian granulosa cells, which is known to be stimulated by FSH and, in turn, to suppress FSH, may play a role in the altered physiology of the perimenopause (Klein NA, et al., 1996, 1998). Increasing evidence suggests that ovarian inhibin plays a role in ovarian folliculogenesis (McLachlan RI, et al., 1986; Hughes EG, et al., 1992), therefore, new information about inhibin levels and their functional relationships in women in their forties and fifties becomes important.

The peri and post-menopausal ovary contains two different populations of cells with steroidogenic capacity: hilar cells and cortical stromal cells that may represent residual thecal elements (De Roux N, et al., 1999). In vitro studies suggest that the post-menopausal ovary has some steroidogenic potential. Incubation of post-menopausal ovarian stromal slices with pregnenolone yielded progesterone, dehydroepiandrosterone, and testosterone. Incubation of strips of ovarian hilar tissue from postmenopausal women revealed a steroidogenic pattern similar to that of the postmenopausal ovarian stroma. However, the overall amount of steroids produced was substantially greater compared with stroma. Measurable in vitro formation of estradiol by postmenopausal cortical stroma and hilar cells has also been reported (Bertherat J 1998; Ulloa-Aguirre A, et al., 1998).

With increasing age, the adrenal contribution of precursors for estrogen production proves inadequate. In this final stage of estrogen availability, levels are insufficient to sustain secondary sex tissues. Estrogens in peri and post-menopausal women appear to arise almost exclusively from extra-glandular aromatization of androstenedione (Arora KK, et al., 1997). Oophorectomy results in no significant reduction in urinary estrogen excretion by post-menopausal women. However, adrenalectomy after oophorectomy virtually eliminates measurable estrogens from the urine. In vitro studies concluded that the postmenopausal ovarian stroma is unable to aromatize androgens (Everest HM, et al., 2001). However, others have suggested that the post-menopausal ovary may synthesize limited amounts of estrogens, because the concentrations of estradiol and estrone are two times higher in ovarian venous blood than in peripheral blood of post-menopausal women (Illing N, et al., 1999).

There is some evidence that ovarian androgen production in post-menopausal women can be gonadotropin dependent. Administration of hCG to postmenopausal women results in a small increase in the circulating levels of testosterone (Sun YM, et al.). Daily injection of hCG causes hyperplasia of the ovarian hilar cells and histochemical evidence suggestive of active steroidogenesis (Tensen C, et al., 1997). Administration of hCG, but not ACTH, resulted in increased androgen but not estrogen production by the ovaries (Wang L, et al., 2001). Binding sites for both LH and FSH were identified in the cortical stroma and in hilar cells (Davidson JS, et al., 1994). Addition of hCG to hilar cells results in increased cAMP formation and steroid biosynthesis, indicating preserved responsiveness to gonadotropins. Taken together, these observations suggest that ovarian androgen biosynthesis of the post-reproductive ovary is at least partially gonadotropin dependent.

The post-menopausal ovary is occasionally involved in pathologic endocrine activity. Stromal hyperplasia can occur, with the ovary enlarging with hyperplastic stromal nodules consisting of lipid-rich luteinized cells that resemble theca interna. The ovaries with stromal hyperplasia produce large amounts of androstenedione, resulting in hirsutism and virilisation (Vrecl M, et al., 1998). Hilar cells can give rise to functional hilar cell tumors, which produce excess amounts of androgens, leading to virilisation (Pawson AJ, et al., 1998; Blumenrohr M, et al., 1999; Heding A, et al., 2000). Signs and symptoms of estrogen excess may also be evident in circumstances of significant peripheral aromatization.

6. Treatment of anovulation

If no primary pathology is apparent, or if the primary pathology has been treated appropriately without restoration of normal endocrinology, treatment options lie between estrogen replacement (or the oral contraceptive in a younger woman) to prevent osteoporosis and ovulation induction to restore fertility. Estrogen antagonists usually are ineffective in inducing ovulation in progestogen-negative women, and treatment with pulsatile GnRH or gonadotropin treatment is normally required. (Elizur SE, et al., 2005). Treatment with pulsatile GnRH involves the woman carrying a small portable pump but has the important advantage of a lower multiple pregnancy rates than is seen with gonadotropin treatment. Women with a low LH concentration (<4 IU/L) require treatment with combined gonadotropin treatment regimens that include both FSH and LH bioactivity. The older urinary gonadotropin preparations have sufficient LH bioactivity, but when a recombinant FSH is used, it must be supplemented with recombinant LH or with a low dosage of urinary hCG.

6.1 Ovulation inductions and assisted reproduction

The reproductive period in women is characterized by their ability to ovulate. Ovulation, the release of an oocyte within the peritoneal cavity, follows rupture of a dominant follicle, developed in response to stimulation by endogenous gonadotropins. In the presence of normal fallopian tubes, the released oocyte will be able to interact with spermatozoa ascending the female genital tract. This may lead to production of the zygote and establishment of pregnancy if implantation occurs. When ovarian activity is disrupted, no ovulation takes place and, as a consequence, achievement of pregnancy is not feasible.

Ovulation induction refers to exogenous direct or indirect stimulation of the ovary with the aim of alleviating sub-fertility due to anovulation. Ovulation induction should be differentiated from *reestablishment of ovulation*, which occurs after treatment of conditions interfering with the normal function of the hypothalamic-pituitary-ovarian (HPO) axis. These include weight and eating disorders, thyroid dysfunction, hyper-prolactinemia, and excess exercise. It should also be differentiated from *enhancement of ovulation*. This is usually performed in ovulatory women with unexplained infertility in the hope of increasing the probability of pregnancy. More important, ovulation induction must be differentiated from superovulation for in vitro fertilization (IVF), in which the aim of ovarian stimulation is to induce multi-follicular development. This leads to the retrieval of multiple oocytes and thus allows the selection of the morphologically best embryo(s) for replacement. In IVF, follicular rupture is not necessary, because oocytes are collected by trans-vaginal aspiration (Pelinck MJ, et al., 2001; Castelo-Branco A, et al., 2004; Kolibianakis E, et al., 2002,2003).

6.2 Ovarian stimulation regimens

The ideal ovarian stimulation regimen for IVF should have a low cancellation rate, minimize drug costs, risks and side effects, require limited monitoring for practical convenience, and maximize singleton pregnancy rates. Numerous regimens have been described, ranging from no stimulation (natural cycles), to minimal stimulation (clomiphene citrate) or mild stimulation (sequential treatment with clomiphene citrate and low dose exogenous gonadotropins), to aggressive stimulation (high dose exogenous gonadotropins, alone or in combination with a gonadotropin-releasing hormone agonist or antagonist). Ovarian stimulation has been a basic element of IVF for more than 25 years, but concerns about

multiple pregnancies and the costs of IVF have sparked renewed interest in natural cycle IVF and mild stimulation regimens (Nargund G, et al., 2001)

7. Natural cycle

The first birth resulting from IVF derived from a single oocyte collected in a natural ovulatory cycle (Steptoe PC, & Edwards RG, 1978). Compared to stimulated IVF cycles, natural cycle IVF offers a number of attractive advantages. Natural cycle IVF involves only monitoring the spontaneous cycle and retrieving a single oocyte before the midcycle LH surge occurs. It is physically less demanding, requires little or no medication, decreases costs by 75–80%, (Aboulghar MA, et al., 1995; Nargund G, et al., 2001) and all but eliminates risks for multiple pregnancy and ovarian hyper-stimulation syndrome (OHSS). The chief disadvantages of natural cycle IVF are high cancellation rates due to premature LH surges and ovulation, and the comparatively low success rate, which is approximately 7% (Pelinck MJ, et al., 2002). When oocyte retrieval is based on detection of the mid-cycle rise in LH, careful and frequent monitoring is required and procedures are difficult to schedule efficiently.

Alternatively, exogenous human chorionic gonadotropin (hCG) can be administered when the lead follicle reaches a size consistent with maturity, thereby better defining the optimum time for oocyte retrieval (Nargund G, et al., 2001). Adjuvant treatment with a GnRH antagonist also can be used to prevent a premature LH surge, but requires “add-back” treatment with exogenous FSH, and success rates are still quite low, ranging up to 14% per cycle in non-randomized trials (Castelo-Branco A, et al., 2004; Kolibianakis E, et al., 2002, 2003; Weghofer A, et al., 2004; Elizur SE, et al., 2005). In one large cohort study involving 844 treatment cycles in 350 good prognosis patients, the cancellation rate was 13%, the pregnancy rate was 8% per cycle and the cumulative pregnancy rate after three “modified natural IVF cycles” was 21% (Pelinck MJ, et al., 2002). In a cohort of infertile couples with male factor infertility, success rates in modified natural cycles have reached as high as 13% per cycle, with a cumulative pregnancy rate of 44% after six treatment cycles (Verberg MF, et al., 2006).

8. Clomiphene citrate

Clomiphene citrate (CC) was the first method of ovarian stimulation used in IVF, (Quigley MM, et al., 1984) but now has been almost entirely replaced by more effective stimulation regimens using human menopausal gonadotropins (hMG) or FSH, in combination with a GnRH agonist or antagonist (Macklon NS, et al., 2006). Clomiphene (100 mg daily) usually is administered for 5–8 days, beginning on cycle day 3, and induces development of two or more follicles in most normally ovulating women, (Dickey RP, et al., 1998; Messinis IE & Milingos SD 1998; Ingerslev HJ, et al., 2001) although egg yields 1–3, are only slightly greater than in un-stimulated cycles and substantially lower than in cycles stimulated with exogenous gonadotropins (Ingerslev HJ, et al., 2001; Branigan EF & Estes MA 2000; MacDougall MJ, Tan SL, Hall V, et al., 1996).

Cycle cancellation rates are somewhat lower than in natural cycles and the numbers of oocytes retrieved, embryos transferred, and pregnancy rates are greater. As in natural stimulates multi-follicular development more effectively than treatment with Clomiphene alone (Corfman RS, et al., 1993; Dor J, et al., 1992). Drug costs and monitoring requirements

are moderately cycles, exogenous hCG is administered when the lead follicle reaches mature size and a GnRH antagonist can be used to prevent a premature endogenous LH surge. Sequential treatment with clomiphene (100 mg daily for 5 days) and modest doses of exogenous gonadotropins (150–225 IU daily beginning on the last day of clomiphene treatment or the day after) higher, but still substantially less than in standard stimulation regimens involving higher dose gonadotropin treatment after down-regulation with a long-acting GnRH agonist (described below) (Weigert M, et al., 2002; Dhont M, et al., 1995). In one comparative trial, higher cancellation rates and lower pregnancy rates were observed in sequential clomiphene/gonadotropin cycles (Dhont M, et al., 1995). In another, the sequential stimulation regimen yielded fewer oocytes and embryos, but pregnancy rates were similar and the risks of ovarian hyper-stimulation syndrome (OHSS) were lower (Weigert M, et al., 2002).

In a randomized trial, sequential clomiphene/gonadotropin stimulation and GnRH antagonist treatment yielded a pregnancy rate comparable to that achieved with a more aggressive standard treatment protocol, (Lin YH, et al., 2006) confirming the results of two earlier retrospective studies, (Fiedler K & Ludwig M 2003; Williams SC, et al., 2002), but contrasting with those of another observing lower pregnancy rates (Mansour R, et al., 2003).

9. GnRH agonist “flare” gonadotropins stimulation protocol

The “short” or “flare” protocol is an alternative stimulation regimen designed to exploit both the brief initial agonistic phase of response to a GnRH agonist and the suppression that results from longer-term treatment (Padilla SL, et al., 1996; Garcia JE, et al., 1990). In a typical standard short protocol, leuprolide acetate (1.0 mg daily) is administered on cycle days 2–4, continuing thereafter at a reduced dose (0.5 mg daily), and gonadotropin stimulation (225–450 IU daily) begins on cycle day 3. Later adjustments in the dose of gonadotropin stimulation, if needed, are based on response and indications for hCG administration are the same as in the long protocol (described above). An early meta-analysis including seven clinical trials comparing the short and long GnRH agonist treatment regimens determined that the two protocols yielded similar cancellation and pregnancy rates: (Hughes EG, et al., 1992).

A 2000 systematic review including 22 trials concluded that pregnancy rates achieved with the long protocol were superior to those using the flare regimen (OR=1.27, CI=1.04–1.56) overall, (Daya S., 2000), but the analysis did not control for diagnosis and other prognostic factors and results may not apply to all women, or to poor responders in particular. Whereas some have observed improved follicular response and lower cycle cancellation rates in poor responders treated with a flare protocol, pregnancy and live birth rates remained low (Karande V, et al., 1997; Karacan M, et al., 2001). Decreased scheduling flare exhibility is a distinct disadvantage of the flare is protocol, unless the onset of menses is controlled by preliminary treatment with an OC. The regimen also can result in a significant increase in serum progesterone and androgen levels, presumably resulting from late corpus luteum rescue, (San Roman GA, et al., 1992) which may adversely affect oocyte quality and fertilization and pregnancy rates (Loumaye E, et al., 1989). The “OC micro-dose GnRH agonist flare” stimulation regimen is a variation of the standard short protocol involving 14–21 days of preliminary ovarian suppression with an OC (one pill daily), followed by micro-dose leuprolide treatment (40 µg twice daily) beginning 3 days after discontinuation of OC treatment, and high-dose gonadotropin stimulation (300–450 IU daily) starting on day 3 of

leuprolide therapy. Indications for later gonadotropin dose adjustments and hCG administration are the same as in other stimulation regimens. Its primary advantage over the standard short protocol is that it does not induce any increases in serum progesterone or androgen concentrations, possibly because the doses of GnRH agonist administered are much lower, but likely also because preliminary OC treatment all but eliminates the possibility there may be a corpus luteum left to respond (Gonen Y, et al., 1990; Cedrin-Durnerin et al., 1996). The OC-micro-dose GnRH agonist flare protocol may be useful in previous poor responders, in whom it can stimulate increased endogenous FSH release and may yield lower cancellation rates and higher peak serum estradiol levels, transfer rates and pregnancy rates (Surrey ES, et al., 1998; Scott RT et al., 1994) GnRH Antagonist Gonadotropin Stimulation Protocol.

The introduction of GnRH antagonists into clinical practice provided another option for ovarian stimulation in ART. In contrast to the long-acting agonists, which first stimulate and later inhibit pituitary gonadotropin secretion by desensitizing gonadotropes to GnRH via receptor down-regulation, the antagonists block the GnRH receptor in a dose-dependent competitive fashion and have no similar flare effect (Matikainen T, et al., 1992; Reissmann T, et al., 1974,1995) gonadotropin suppression is almost immediate. GnRH antagonists offer several potential advantages over agonists. First, the duration of treatment for an antagonist is substantially shorter than for an agonist. Since its only purpose is to prevent a premature endogenous LH surge and its effects are immediate, antagonist treatment can be postponed until later in follicular development (after 5–6 days of gonadotropin stimulation), after estradiol levels are already elevated, thereby eliminating the estrogen deficiency symptoms that may emerge in women treated with an agonist (Olivennes F, et al., 2002).

Second, because any suppressive effects that agonists may exert on the ovarian response to gonadotropin stimulation also are eliminated, the total dose and duration of gonadotropin stimulation required is decreased (Olivennes F, et al., 2002; Albano C, et al., 2000). For the same reason, GnRH antagonist stimulation protocols may benefit women who are poor responders when treated with a standard long protocol (Olivennes F, et al., 2003; Akman MA, et al., 2001). Third, by eliminating the flare effect of agonists; GnRH antagonists avoid the risk of stimulating development of a follicular cyst. Finally, the risk of severe OHSS associated with use of antagonists also appears lower than with agonists. GnRH antagonists have some potential disadvantages. When administered in small daily doses, strict compliance with the prescribed treatment regimen is essential (Olivennes F, et al., 2002).

Antagonists suppress endogenous gonadotropin secretion more completely than agonists. Whereas the low levels of LH observed during agonist treatment are usually sufficient to support normal follicular steroid-genesis during stimulation with uFSH or rFSH, the even lower concentrations in women treated with an antagonist may not be. Indeed, serum estradiol levels may plateau or fall when antagonist treatment begins (Olivennes F, et al 2002; de Jong D, et al., 2001). Although follicular growth appears unaffected, most prefer to add or substitute a low dose of hMG (75 IU) at the same time if it was not already part of the stimulation regimen. Evidence also suggests that pregnancy rates in antagonist treatment cycles may be modestly lower than in cycles using agonists in the long protocol (Al-Inany et al., 2006).

The two GnRH antagonists available for clinical use, ganirelix and cetrorelix, are equally potent and effective. For both, the minimum effective dose to prevent a premature LH surge is 0.25 mg daily, administered sub-cutaneously (Albano C, et al., 1997). Either can be administered in a series of small daily doses (0.25 mg). The treatment protocol may be fixed

and begin after 5–6 days of gonadotropin stimulation, (Albano C, et al., 1997; Diedrich K, et al., 1994), or tailored to the response of the individual, starting treatment when the lead follicle reaches approximately 13–14 mm in diameter. The individualized treatment regimen generally requires fewer total doses and may yield better overall results (Ludwig M, et al., 2002). Alternatively, a single larger dose of cetrorelix (3.0 mg) will effectively prevent an LH surge for 96 hours. If given on day 6–7 of stimulation, the interval of effective suppression will encompass the day of hCG administration in most women (75–90%); the remainder may receive additional daily doses (0.25 mg) as needed, ending on the day of hCG treatment (Olivennes F, et al 1995; Olivennes F, et al., 2000; Olivennes F, et al., 2003). The single dose antagonist treatment regimen also can be withheld until the lead follicle reaches 13–14 mm in diameter (Fanchin R, et al., 2003,2005).

A common variation of the antagonist stimulation regimen uses preliminary treatment with an OC to control the onset of menses, typically ending approximately 5 days before the scheduled start, which also may help to synchronize the follicular cohort before stimulation begins. Another variation advocated for poor responders uses micronized estradiol (2 mg twice daily, administered orally, beginning on day 21 of the preceding cycle) to suppress FSH during the late luteal phase for the same purpose, ending on the day before gonadotropins stimulation begins, (Fanchin R, et al 2003, 2005), or continuing through the first 3 days of gonadotropin stimulation (Hill MJ, et al., 2009). The improved follicular dynamics observed are similar to those achieved by down-regulation with a GnRH agonist in the long protocol. The rebound increase in endogenous FSH levels that follows the discontinuation of estradiol treatment also may synergize with exogenous gonadotropins to promote multi-follicular development (de Ziegler D, et al., 1998; Fanchin R, et al., 2003). Results of a number of early trials comparing a fixed antagonist treatment protocol to the standard long protocol suggested that the two stimulation regimens yielded similar pregnancy rates (Albano C, et al., 2000; Olivennes F, et al., 2000); The European Middle East Orgalutran Study Group, 2001; Fluker M, et al., 2001). However, a 2006 systematic review and meta-analysis including 27 trials comparing different antagonist stimulation protocols with the long GnRH agonist protocol observed a significantly lower clinical pregnancy rate (OR=0.84, CI=0.72–0.97) and ongoing pregnancy/live birth rate (OR=0.82, CI=0.69–0.98). Overall, the total dose and duration of gonadotropin stimulation required, peak serum estradiol levels, and the number of follicles and oocytes were lower in antagonist cycles.

The explanation for the modestly lower pregnancy rates observed in antagonist treatment cycles is not clear. It is possible, but unlikely, that GnRH antagonists may have adverse effects on oocytes, embryos, or the endometrium (Hernandez ER 200; Ortmann O, et al., 2001). It is far more likely that early results reflected inexperience and improved with time and further refinements in the treatment regimen like those described above. Many of the advantages originally envisioned for GnRH antagonists already have been realized. Whether antagonists ultimately will replace agonists and become the standard ovarian stimulation regimen in ART cycles remains to be seen, but their place in the therapeutic arsenal already is firmly established. Whereas a single bolus injection of an agonist (leuprolide 0.5 mg, triptorelin 0.2 mg) triggers a physiologic LH surge that lasts less than 24 hours, hCG levels remain elevated for several days and stimulate markedly higher estradiol and progesterone concentrations (Fauser BC, et al., 2002).

The antagonist treatment regimens currently in use have potential disadvantages for women with PCOS. Their tonically elevated LH levels will remain high until antagonist treatment begins. Consequently, LH levels may rise prematurely, particularly if antagonist treatment

is withheld until the lead follicle reaches 14 mm or more. Moreover, evidence indicates that increased LH exposure during early follicular development may be detrimental and predispose to lower pregnancy rates (Kolibianakis E, et al., 2002; Kolibianakis EM, et al., 2003; Kolibianakis EM, et al., 2003; Kolibianakis E, et al., 2003). In theory, pre-treatment with an OC might prove quite useful by suppressing LH and androgen levels before stimulation begins, decreasing exposure during early follicular development and the risk of rising LH levels before antagonist treatment starts. Preliminary OC suppression and later antagonist treatment may help to limit the follicular response to gonadotropin stimulation while preserving the option to use an agonist to trigger final oocyte maturation. These considerations simply serve to illustrate that GnRH antagonists are not a panacea and are not necessarily the best choice even for women with PCOS. Antagonist stimulation protocols are advocated for poor responders, primarily because they avoid the suppressive effects that agonists can have on follicular response and can prevent the premature LH surges observed commonly in women stimulated with gonadotropins alone (Surrey ES & Schoolcraft WB., 2000). However, evidence is insufficient to indicate they yield results consistently better than other stimulation regimens (Pandian Z, et al., 2010; Centers for Disease Control and Prevention, Atlanta, GA, 2009).

10. Ovarian reserve

The concept of ovarian reserve, generally defined as the size and quality of the remaining ovarian follicular pool, and the various methods for its measurement. The total number of oocytes in any given woman is genetically determined and inexorably declines throughout life, from approximately 1-2 million at birth, to about 300,000 at puberty, 25,000 at age 40, and fewer than 1,000 at menopause (Battaglia DE, et al., 1996; Faddy MJ & Gosden RG, 1996). The rate of follicular depletion is not constant, but increases gradually as the number of follicles remaining decreases (Nilsson E, et al., 2007; Adhikari D & Liu K, 2009; Da Silva-Buttkus P, et al., 2009; Coxworth JE, & Hawkes K, 2010). As the size of the remaining follicular pool decreases, circulating inhibin-B levels (derived primarily from smaller antral follicles) decrease, resulting in lower levels of feedback inhibition and a progressive increase in serum follicle-stimulating hormone (FSH) levels, most noticeably during the early follicular phase (Klein NA, et al., 1996; Welt CK, McNicholl DJ, Taylor AE, et al.; Hale GE, et al., 2007; Knauff EA, et al., 2009; Burger HG, et al., 2008). Increasing inter-cycle FSH concentrations stimulate earlier follicular recruitment, resulting in advanced follicular development early in the cycle, an earlier rise in serum estradiol levels, a shorter follicular phase, and decreasing overall cycle length (Klein NA, et al., 2002; de Koning CH, et al., 2008).

The physiology of reproductive aging provides the foundation for all contemporary tests of ovarian reserve. In clinical practice, the basal early follicular phase (cycle day 2-4) FSH level is the most common test, but antimüllerian hormone (AMH) and antral follicle count are alternatives having significant potential advantages. As basal FSH levels increase, peak estradiol levels during stimulation, the number of oocytes retrieved, and the probability for pregnancy or live birth decline steadily (Pearlstone AC, et al., 1992; Scott Jr RT & Hofmann GE, 1995; Bukman A, & Heineman MJ, 2001). With current assays (using IRP 78/549), FSH levels greater than 10 IU/L (10-20 IU/L) have high specificity (80-100%) for predicting poor response to stimulation, but their sensitivity for identifying such women is generally low (10-30%) and decreases with the threshold value (Broekmans FJ, et al., 2006). Although

most women who are tested have a normal result, including those with a diminished ovarian reserve (DOR), the test is still useful because those with abnormal results are very likely to have DOR. In a 2008 study, an FSH concentration above 18 IU/L had 100% specificity for failure to achieve a live birth (Scott Jr RT, et al., 2008). The basal serum estradiol concentration, by itself, has little value as an ovarian reserve test (Hazout A, et al., 2004; Eldar-Geva T, et al., 2005; McIlveen M, et al., 2007), but can provide additional information that helps in the interpretation of the basal FSH level. An early elevation in serum estradiol reflects advanced follicular development and early selection of a dominant follicle (as classically observed in women with advanced reproductive aging), and will suppress FSH concentrations, thereby possibly masking an otherwise obviously high FSH level indicating DOR. When the basal FSH is normal and the estradiol concentration is elevated ($>60\text{--}80\text{ pg/mL}$), the likelihood of poor response to stimulation is increased and the chance for pregnancy is decreased (Evers JL, et al., 1998; Buyalos RP, al., 1997). When both FSH and estradiol are elevated, ovarian response to stimulation is likely to be very poor. Antimüllerian hormone (AMH) derives from pre-antral and small antral follicles. Levels are gonadotropin-independent and vary little within and between cycles (Fanchin R, et al., 2005; Tsepelidis S, et al., 2007; Hehenkamp WJ, et al., 2006). The number of small antral follicles correlates with the size of the residual follicular pool and AMH levels decline progressively with age, becoming undetectable near the menopause (Sowers MR, et al., 2008; van Rooij IA, et al., 2004; van Rooij IA, et al., 2005).

10.1 Oocyte and ovarian tissue cryopreservation

Each year, cancer occurs in approximately 100 per 100,000 women under age 50 in the United States. Chemotherapy and radiation therapy for malignant and non-malignant systemic disease very often results in ovarian failure. Women with cancer and other serious illnesses requiring treatments that pose a serious threat to their future fertility have relatively few options. In some cases, the ovaries may be moved out of the radiation field. Treatment with GnRH agonists has been suggested as a way to protect the gonads from the insult of chemotherapy, but there is no convincing evidence for its efficacy. Although embryo banking is effective, the time required for stimulation and retrieval are often prohibitive. With recent advances in cryobiology, oocyte and ovarian tissue cryopreservation hold promise as methods to preserve reproductive potential (Shaw JM, et al., 2000).

10.2 Oocyte cryopreservation

Although the first pregnancy resulting from oocyte cryopreservation was reported in 1986, (Chen C, 1986), success rates achieved with the technology were historically very low, and only recently improving. The primary obstacle was the poor survival of oocytes, which are fragile due to their size, high water content, and chromosomal arrangement; the meiotic spindle is easily damaged by intracellular ice formation during freezing or thawing (Shaw JM, et al., 2000). Germinal vesicle stage oocytes are hardier, (Boiso I, et al., 2002), but progress with in vitro maturation of immature oocytes has been slow. Another obstacle was hardening of the zona pellucida, which interfered with normal fertilization. The improved survival of cryopreserved oocytes today relates primarily to modifications in the sucrose and sodium concentrations in traditional “slow-freeze” protocols, (Fabbri R, et al., 2001; Stachecki JJ & Willadsen SM, 2000; Bianchi V, et al., 2007; De Santis L, et al., 2007), changes,

in the initial temperature of the cryoprotectant, and-seeding temperature (Trad FS, et al., 1999). Survival rates have been further improved with vitrification, a technique that uses high concentrations of cryoprotectant and rapid freezing by immersion in liquid nitrogen, preserving oocytes in a solid glass-like state without ice formation (Loutradi KE, et al., 2008; Oktay K, et al., 1997). With the use of intra-cytoplasmic sperm injection (ICSI), the hardened zona is not a barrier to fertilization (Polak de Fried E, et al., 1998). Survival, fertilization, and pregnancy rates achieved with cryopreserved oocytes are rapidly improving and approaching those achieved with fresh oocytes (Grifo JA, & Noyes N, 2010; Nagy ZP, et al., 2009). A randomized comparison of results achieved with slow-freeze and vitrification observed that vitrification resulted in better oocyte survival (81% vs. 67%), fertilization (77% vs. 67%), and clinical pregnancy rates per thawed oocyte (5.2% vs. 1.7%).

A study examining outcomes achieved with vitrified donor oocytes observed 87% thaw survival, 87% fertilization, and 68% blastocyst formation, with 15/20 recipients (75%) achieving pregnancy after embryo transfer (Cobo A, Kuwayama M, Perez S, et al). Another using both slow-frozen and vitrified oocytes observed 92% survival, 79% fertilization, 42% implantation, and a 57% on going pregnancy rate (Grifo JA & Noyes N, 2010). Although the number of pregnancies and deliveries resulting from oocyte cryopreservation is still somewhat small, the number is rapidly increasing, and early perinatal outcomes data are reassuring. The incidence of chromosomal abnormalities in human embryos derived from cryopreserved oocytes is no different from that observed in control embryos derived from fresh oocytes (Gook DA, et al., 1994; Cobo A, et al., 2001). A study comparing outcomes in 200 infants derived from vitrified oocytes and in infants resulting from conventional fresh IVF found no differences in birth weight or in the incidence of birth defects (Chian RC, et al., 2008). A review of over 900 live births resulting from IVF of cryopreserved oocytes also observed no increase in the prevalence of congenital anomalies compared to that in the general population (Noyes N, et al., 2009). Oocyte cryopreservation is a viable fertility preservation strategy for women without partners seeking to preserve their fertility. Unfortunately few cancer patients have sufficient time to undergo ovarian stimulation before their treatment begins. The technology also holds enormous promise as a means to simplify oocyte donation, via egg banking, and is rapidly emerging as an elective fertility preservation strategy for women anticipating delayed childbearing and concerned about their future fertility. Currently, elective oocyte cryopreservation to defer reproductive aging is controversial, primarily because the great majority of outcomes data have come from experience with cryopreserved oocytes obtained from healthy young oocyte donors and cannot be extrapolated to older women who represent the majority of those expressing interest in elective oocyte cryopreservation (Rybak EA & Lieman HJ 2009; ASRM Practice Committee). However, when age-stratified outcomes data become available, allowing women to be accurately informed about their prognosis for success, elective oocyte cryopreservation may realistically offer women the means to set their "biological clock."

10.2.1 Ovarian tissue cryopreservation

At least in theory, ovarian tissue cryopreservation offers the means to freeze thousands of primordial follicles for later in vitro maturation or to store tissue for xenografting into an animal host or later auto transplantation (Jeruss JS, Woodruff TK., 2009). Currently, autologous transplantation of ovarian tissue seems the most practical and effective approach

because the technique has successfully restored fertility to women with ovarian failure resulting from cancer chemotherapy (Andersen CY, et al., 2008; Demeestere I, 2006,2010; et al; Silber SJ 2009). Ovarian tissue is removed surgically via laparoscopy or laparotomy and frozen using either a slow-cool or vitrification technique, before the insult expected to result in ovarian failure. Later, it can be thawed and transplanted back into the patient in or near its original location (orthotopic transplantation) or to another site, such as the forearm or abdominal wall (heterotopic transplantation). The advantage of orthotopic transplantation is that pregnancy might be achieved without assistance, whereas heterotopic transplantation requires IVF (Jeruss JS & Woodruff TK. 2009). Live births have been achieved after transplantation of frozen-thawed ovarian tissue in sheep, (Candy CJ et al., 2000) and the first live birth in a primate after a fresh heterotopic ovarian transplantation has been reported (Lee DM, et al). Human oocytes have been obtained from heterotopic transplants and fertilized in vitro to yield embryos for transfer, resulting in a biochemical pregnancy (Rosendahl M, et al., 2006). The only human pregnancy achieved after heterotopic transplantation was achieved without assistance, indicating that the oocyte from which it arose came from the patient's existing ovary rather than from the transplant. Orthotopic transplantation has been successfully achieved in humans.

A number of live births have been reported after autologous orthotopic transplantation of cryopreserved ovarian tissue. Frozen ovarian tissue also has been transplanted successfully between monozygotic twin sisters after the receiving twin developed premature ovarian failure (Silber SJ, & Gosden RG, 2007). A 2008 systematic review identified 25 reports describing a total of 46 cases of ovarian tissue transplantation for treatment of premature ovarian failure or infertility, although most involved transplantation of fresh rather than frozen ovarian tissue (Bedaiwy MA, et al., 2008). The mean time to return of ovarian function was 120 days (range 60–244 days) and data were insufficient to evaluate function beyond 1 year. Fresh grafts were more likely to succeed, and in 25 women who sought pregnancy, eight conceived nine pregnancies. At least one potential risk of ovarian tissue cryopreservation and auto-transplantation is reseeding of tumor cells in women with malignancies. Future research focusing on defining patient suitability, tissue collection methods, and cryopreservation protocols is certainly warranted, but until effective techniques and the possibility for success can be defined, ovarian tissue cryopreservation will remain investigational and cannot be justified solely for the purpose of future use in healthy women.

11. References

- Aboulghar MA, Mansour RT, Serour GA, Amin YM, Sattar MA, Ramzy AM, In vitro fertilization in a spontaneous cycle: a successful simple protocol, *J Obstet Gynaecol* (Tokyo 1995) 21:337, 1995.
- Adhikari D, Liu K, Molecular mechanisms underlying the activation of mammalian primordial follicles, *Endocr Rev*; 30:438, 2009.
- Ahmed-Ebbiary NA, Lenton EA, Cooke ID: Hypothalamic-pituitary ageing: progressive increases in FSH and LH concentrations throughout the reproductive life in regularly menstruating women. *Clin Endocrinol*; 41:199-206. 1994.
- Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M, Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of

- poor responders: results of a prospective randomized trial, *Hum Reprod* 16:868, 2001.
- Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K, Devroey P, Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group, *Hum Reprod* 15:526, 2000.
- Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P, Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation, *Fertil Steril* 67:917, 1997.
- Al-Inany HG, Abou-Setta AM, Aboulghar M, Gonadotrophinreleasing hormone antagonists for assisted conception, *Cochrane Database Syst Rev* 3:CD001750, 2006.
- Anasti JN: Premature ovarian failure: an update. *Fertil Steril* 70:1-15. 1998.
- Andersen CY, Rosendahl M, Byskov AG, Loft A, Ottosen C, Dueholm M, Schmidt KL, Andersen AN, Ernst E, Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue, *Hum Reprod* 23:2266, 2008.
- Arora KK, Cheng Z, Catt KJ: Mutations of the conserved DRS motif in the second intracellular loop of the gonadotropin-releasing hormone receptor affect expression, activation, and internalization. *Mol Endocrinol*; 11:1203-1212. 1997.
- Bancsi LF, Broekmans FJ, Eijkemans MJ, de Jong FH, Habbema JD, te Velde ER, Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve, *Fertil Steril* 77:328, 2002.
- Battaglia DE, Goodwin P, Klein NA, Soules MR, Influence of maternal age on meiotic spindle assembly in oocytes from naturally cycling women, *Hum Reprod* 11:2217, 1996.
- Bedaiwy MA, El-Nashar SA, El Saman AM, Evers JL, Sandadi S, Desai N, Falcone T, Reproductive outcome after transplantation of ovarian tissue: a systematic review, *Hum Reprod* 23:2709, 2008.
- Belsey EM, Pinol APY, and Task Force on Long-Acting Systemic Agents for Fertility Regulation, Menstrual bleeding patterns in untreated women, *Contraception* 55:57, 1997.
- Bertherat J: Gonadotropin-releasing hormone receptor gene mutation: a new cause of hereditary hypogonadism and another mutated G-protein-coupled receptor. *Eur J Endocrinol*; 138:621-622. 1998.
- Bianchi V, Coticchio G, Distratis V, Di Giusto N, Flamigni C, Borini A, Differential sucrose concentration during dehydration (0.2mol/l) and rehydration (0.3 mol/l) increases the implantation rate of frozen human oocytes, *Reprod Biomed Online* 14:64, 2007.
- Blomenrohr M, Heding A, Sellar R, et al: Pivotal role for the cytoplasmic carboxyl-terminal tail of a nonmammalian gonadotropin-releasing hormone receptor in cell surface expression, ligand binding, and receptor phosphorylation and internalization. *Mol Pharmacol*; 56:1229-1237. 1999.
- Boiso I, Marti M, Santalo J, Ponsa M, Barri PN, Veiga A, A confocal microscopy analysis of the spindle and chromosome configurations of human oocytes cryopreserved at the germinal vesicle and metaphase II stage, *Hum Reprod* 17:1885, 2002.

- Branigan EF, Estes MA, Minimal stimulation IVF using clomiphene citrate and oral contraceptive pill pre-treatment for LH suppression, *Fertil Steril* 73:587, 2000.
- Braunstein GD, Sundwall DA, Katz M, et al: Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. *Arch Intern Med*; 165:1582-1589. 2005.
- Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB, A systematic review of tests predicting ovarian reserve and IVF outcome, *Hum Reprod Update* 12:685, 2006.
- Bromberger JT, Matthews KA, Kuller LH, et al: Prospective study of the determinants of age at menopause. *Am J Epidemiol*; 145:124-133. 1997.
- Buckler HM, Evans A, Mamlora H, Burger HG, Anderson DC, Gonadotropin, steroid and inhibin levels in women with incipient ovarian failure during anovulatory and ovulatory 'rebound' cycles, *J Clin Endocrinol Metab* 72:116, 1991.
- Bukman A, Heineman MJ, Ovarian reserve testing and the use of prognostic models in patients with subfertility, *Hum Reprod Update* 7:581, 2001.
- Burger HD, Dudley EC, Hooper JL, et al: The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. *J Clin Endocrinol Metab* ; 80:3537-3545. 1995.
- Burger HG 1993 Editorial: Clinical utility of inhibin measurements. *J Clin Endocrinol Metab* 76:1391-1396.
- Burger HG, Dudley E, Manners P, Groome N, Robertson DM, Early follicular phase serum FSH as a function of age: the roles of inhibin B, inhibin A and estradiol, *Climacteric* 3:17, 2000.
- Burger HG, Dudley EC, Cui J, et al: A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. *J Clin Endocrinol Metab*; 85:2832-2838. 2000.
- Burger HG, Dudley EC, Robertson DM, et al: Hormonal changes in the menopause transition. *Recent Prog Horm Res*; 57:257-275. 2002.
- Burger HG, Hale GE, Dennerstein L, Robertson DM, Cycle and hormone changes during perimenopause: the key role of ovarian function, *Menopause* 15:603, 2008.
- Burger HG, Hale GE, Dennerstein L, Robertson DM, Cycle and hormone changes during perimenopause: the key role of ovarian function, *Menopause* 15:603, 2008.
- Burger HG, Hale GE, Robertson DM, et al: A review of the hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. *Hum Reprod Update*; 13:559-565. 2007.
- Buyalos RP, Daneshmand S, Brzechffa PR, Basal estradiol and follicle-stimulating hormone predict fecundity in women of advanced reproductive age undergoing ovulation induction therapy, *Fertil Steril* 68:272, 1997.
- Candy CJ, Wood MJ, Whittingham DG, Restoration of a normal reproductive lifespan after grafting of cryopreserved mouse ovaries, *Hum Reprod* 15:1300, 2000.
- Castelo-Branco A, Frydman N, Kadoch J, Le Du A, Fernandez H, Fanchin R, Frydman R, The role of the semi natural cycle as option of treatment of patients with a poor prognosis for successful in vitro fertilization, *J Gynecol Obstet Biol Reprod (Paris)* 33:518, 2004.

- Cedrin-Durnerin I, Bulwa S, Herve F, Martin-Pont B, Uzan M, Hugues JN, The hormonal fl are-up following gonadotrophin-releasing hormone agonist administration is influenced by a progestogen pretreatment, *Hum Reprod* 11:1859, 1996.
- Centers for Disease Control and Prevention, 2007 Assisted Reproductive Technology Success Rates. National Summary and Fertility Clinic Reports. Atlanta, GA, 2009.
- Chian RC, Huang JY, Tan SL, Lucena E, Saa A, Rojas A, Ruvalcaba astellon LA, Garcia Amador MI, Montoya Sarmiento JE, Obstetric and perinatal outcome in 200 infants conceived from vitrified oocytes, *Reprod Biomed Online* 16:608, 2008.
- Cobo A, Kuwayama M, Perez S, Ruiz A, Pellicer A, Remohi J, Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrifi ed by the Cryotop method, *Fertil Steril* 89:1657, 2008.
- Cobo A, Rubio C, Gerli S, Ruiz A, Pellicer A, Remohi J, Use of fluorescence in situ hybridization to assess the chromosomal status of embryos obtained from cryopreserved oocytes, *Fertil Steril* 75:354, 2001.
- Collett ME, Wertenberger GE, Fiske VM, The effect of age upon the pattern of the menstrual cycle, *Fertil Steril* 5:437, 1954.
- Colombat de L'Isere M: Diseases of Women. American edition translated by Meigs CD. Cited by Ricci JV. One Hundred Years of Gynaecology 1800-1900 (1850) Philadelphia, Blakiston Co. p 532. 1945.
- Corfman RS, Milad MP, Bellavance TL, Ory SJ, Erickson LD, Ball GD, A novel ovarian stimulation protocol for use with the assisted reproductive technologies, *Fertil Steril* 60:864, 1993.
- Couzinet B, Meduri G, Lecce MG, et al: The postmenopausal ovary is not a major androgen-producing gland. *J Clin Endocrinol Metab*; 86:5060-5066. 2001.
- Coxworth JE, Hawkes K, Ovarian follicle loss in humans and mice: lessons from statistical model comparison, *Hum Reprod* 25:1796, 2010.
- Cramer DW, Xu H, Harlow BL: Does "incessant" ovulation increase risk for early menopause?. *Am J Obstet Gynecol* ; 172:568-573. 1995.
- Da Silva-Buttkus P, Marcelli G, Franks S, Stark J, Hardy K, Inferring biological mechanisms from spatial analysis: prediction of a local inhibitor in the ovary, *Proc Natl Acad Sci U S A* 106:456, 2009.
- Davidson JS, Wakefield IK, Millar RP: Absence of rapid desensitization of the mouse gonadotropin-releasing hormone receptor. *Biochem J*; 300:299-302. 1994.
- Daya S, Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles, *Cochrane Database Syst Rev*: CD001299, 2000.
- De Jong D, Macklon NS, Eijkemans MJ, Mannaerts BM, Coelingh Bennink HJ, Fauser BC, Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/ Antagon), *Fertil Steril* 75:688, 2001.
- De Koning CH, McDonnell J, Themmen AP, de Jong FH, Homburg R, Lambalk CB, The endocrine and follicular growth dynamics throughout the menstrual cycle in

- women with consistently or variably elevated early follicular phase FSH compared with controls, *Hum Reprod* 23:1416, 2008.
- De Roux N, Young J, Brailly-Tabard S, et al: The same molecular defects of the gonadotropin-releasing hormone receptor determine a variable degree of hypogonadism in affected kindred. *J Clin Endocrinol Metab*; 84:567-572. 1999.
- De Santis L, Cino I, Rabellotti E, Papaleo E, Calzi F, Fusi FM, Brigante C, Ferrari A, Oocyte cryopreservation: clinical outcome of slow-cooling protocols differing in sucrose concentration, *Reprod Biomed Online* 14:57, 2007.
- De Ziegler D, Jaaskelainen AS, Brioschi PA, Fanchin R, Bulletti C, Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH), *Hum Reprod* 13:561, 1998.
- Demeestere I, Simon P, Buxant F, Robin V, Fernandez SA, Centner J, Delbaere A, Englert Y, Ovarian function and spontaneous pregnancy after combined heterotopic and orthotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report, *Hum Reprod* 21:2010, 2006.
- Dhont M, Onghena A, Coetsier T, De Sutter P, Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction, *Hum Reprod* 10:791, 1995.
- Dickey RP, Taylor SN, Rye PH, Lu PY, Future use of clomiphene in ovarian stimulation. A role for clomiphene in the 21st century?, *Hum Reprod* 13:2361, 1998.
- Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmuller D, Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation, *Hum Reprod* 9:788, 1994.
- Dor J, Ben-Shlomo I, Levran D, Rudak E, Yunish M, Mashiach S, The relative success of gonadotropin-releasing hormone analogue, clomiphene citrate, and gonadotropin in 1,099 cycles of in vitro fertilization, *Fertil Steril* 58:986, 1992.
- Dumesic DA, Damario MA, Session DR, Famuyide A, Lesnick TG, Thornhill AR, McNeilly AS, Ovarian morphology and serum hormone markers as predictors of ovarian follicle recruitment by gonadotropins for in vitro fertilization, *J Clin Endocrinol Metab* 86:2538, 2001.
- Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, Gal M, Zylber-Haran E, Margalioth EJ, Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome, *Hum Reprod* 20:3178, 2005.
- El-Hage G, Eden JA, Manga RZ: A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder. *Climacteric*; 10:335-343. 2007
- Elizur SE, Aslan D, Shulman A, Weisz B, Bider D, Dor J, Modified natural cycle using GnRH antagonist can be an optional treatment in poor responders undergoing IVF, *J Assist Reprod Genet* 22:75, 2005.

- Everest HM, Hislop JN, Harding T, et al: Signalling and anti-proliferative effects mediated by GnRH receptors after expression in breast cancer cells using recombinant adenovirus. *Endocrinology*; 142:4663-4672. 2001.
- Evers JL, Slaats P, Land JA, Dumoulin JC, Dunselman GA, Elevated levels of basal estradiol-17beta predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization, *Fertil Steril* 69:1010, 1998.
- Fabbri R, Porcu E, Marsella T, Rocchetta G, Venturoli S, Flamigni C, Human oocyte cryopreservation: new perspectives regarding oocyte survival, *Hum Reprod* 16:411, 2001.
- Faddy MJ, Gosden RG, A model conforming the decline in follicle numbers to the age of menopause in women, *Hum Reprod* 11:1484, 1996.
- Fanchin R, Cunha-Filho JS, Schonauer LM, Kadoch IJ, Cohen- Bacri P, Frydman R, Coordination of early antral follicles by luteal estradiol administration provides a basis for alternative controlled ovarian hyperstimulation regimens, *Fertil Steril* 79:316, 2003.
- Fanchin R, Cunha-Filho JS, Schonauer LM, Righini C, de Ziegler D, Frydman R, Luteal estradiol administration strengthens the relationship between day 3 follicle-stimulating hormone and inhibin B levels and ovarian follicular status, *Fertil Steril* 79:585, 2003.
- Fanchin R, Salomon L, Castelo-Branco A, Olivennes F, Frydman N, Frydman R, Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists, *Hum Reprod* 18:2698, 2003.
- Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, Bouyer J, High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status, *Hum Reprod* 20:923, 2005.
- Fausser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz- Eldor J, van Hooren HG, Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after co-treatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization, *J Clin Endocrinol Metab* 87:709, 2002.
- Ferrell RJ, Simon JA, Pincus SM, Rodríguez G, O'Connor KA, Holman DJ, Weinstein M, The length of perimenopausal menstrual cycles increases later and to a greater degree than previously reported, *Fertil Steril* 86:619, 2006.
- Fiedler K, Ludwig M, Use of clomiphene citrate in in vitro fertilization (IVF) and IVF/intracytoplasmic sperm injection cycles, *Fertil Steril* 80:1521, 2003.
- Findlay JK, Xiao S, Shukovski L The role of inhibin-related peptides as intragonadal regulators. *Reprod Fertil Dev* 2:205-218. 1990.
- Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott Jr RT, Schoolcraft W, Shapiro DB, Efficiency and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation, *Fertil Steril* 75:38, 2001.
- Frattarelli JL, Lauria-Costab DF, Miller BT, Bergh PA, Scott RT, Basal antral follicle number and mean ovarian diameter predict cycle cancellation and ovarian responsiveness in assisted reproductive technology cycles, *Fertil Steril* 74:512, 2000.

- Garcia JE, Padilla SL, Bayati J, Baramki TA, Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization, *Fertil Steril* 53:302, 1990.
- Gold EB, Bromberger J, Crawford S, et al: Factors associated with age at natural menopause in a multiethnic sample of midlife women. *Am J Epidemiol*; 153:865-874. 2001.
- Gonen Y, Jacobson W, Casper RF, Gonadotropin suppression with oral contraceptives before in vitro fertilization, *Fertil Steril* 53:282, 1990.
- Gook DA, Osborn SM, Bourne H, Johnston WI, Fertilization of human oocytes following cryopreservation; normal karyotypes and absence of stray chromosomes, *Hum Reprod* 9:684, 1994.
- Gougeon A, Echiohard R, Thalabard JC, Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women, *Biol Reprod* 50:653, 1994.
- Grifo JA, Noyes N, Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients, *Fertil Steril* 93:391, 2010.
- Grifo JA, Noyes N, Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients, *Fertil Steril* 93:391, 2010.
- Haisenleder DJ, Dalkin AC, Ortolano GA, et al: A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: evidence for differential regulation of transcription by pulse frequency in vivo. *Endocrinology*; 128:509-517. 1991.
- Hale GE, Zhao X, Hughes CL, Burger HG, Robertson DM, Fraser IS, Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system, *J Clin Endocrinol Metab* 92:3060, 2007.
- Hall JE, Lavoie HG, Marsh EE, et al: Decrease in gonadotropin-releasing hormone pulse frequency with aging in postmenopausal women. *J Clin Endocrinol Metab*; 85:1794-1800. 2000.
- Harlow SD, Mitchell ES, Crawford S, Nan B, Little R, Taffe J, for the ReSTAGE Collaboration, The ReSTAGE Collaboration: defining optimal bleeding criteria for onset of early menopausal transition, *Fertil Steril* 89:129, 2008.
- Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen- Bacrie P, Serum anti-mullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol, *Fertil Steril* 82:1323, 2004.
- Heding A, Vrecl M, Hanyaloglu AC, et al: The rat gonadotropin-releasing hormone receptor internalizes via a beta arrestin independent, but dynamin-dependent, pathway: addition of a carboxyl-terminal tail confers beta-arrestin dependency. *Endocrinology*; 141:299-306. 2000.
- Hee J, MacNaughton J, Bangah M, Burger HG, Perimenopausal patterns of gonadotrophins, immunoreactive inhibin, oestradiol and progesterone, *Maturitas* 18:9, 1993.

- Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ, Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation, *J Clin Endocrinol Metab* 91:4057, 2006.
- Hernandez ER, Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists, *Hum Reprod* 15:1211, 2000.
- Hill MJ, McWilliams GD, Miller KA, Scott Jr RT, Frattarelli JL, A luteal estradiol protocol for anticipated poor-responder patients may improve delivery rates, *Fertil Steril* 91:739, 2009.
- Hreinsson JG, Scott JE, Rasmussen C, et al: Growth differentiation factor-9 promotes the growth, development, and survival of human ovarian follicles in organ culture. *J Clin Endocrinol Metab*; 87:316-321. 2002.
- Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA, The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials, *Fertil Steril* 58:888, 1992.
- Hughes EG, Robertson DM, Handelsman DJ, Hayward S, Healy DL, DeKrester DM Inhibin and estradiol responses to ovarian hyper stimulation: effects of age and predictive value for in vitro fertilization outcome. *J Clin Endocrinol Metab*, 70:358-364.,1990.
- Illing N, Troskie BE, Nahorniak CS, et al: Two gonadotropin-releasing hormone receptor subtypes with distinct ligand selectivity and differential distribution in brain and pituitary in the goldfish (*Carassius autatus*). *Proc Natl Acad Sci U S A*; 96:2256-2531. 1999
- Ingerslev HJ, Hojgaard A, Hindkjaer J, Kesmodel U, A randomized study comparing IVF in the unstimulated cycle with IVF following clomiphene citrate, *Hum Reprod* 16:696, 2001.
- Ismael NN: A study of the menopause in Malaysia. *Maturitas*; 19:205-209. 1994.
- Jeruss JS, Woodruff TK, Preservation of fertility in patients with cancer, *New Engl J Med* 360:902, 2009.
- Kaiser UB, Jakubowiak A, Steinberger A, et al: Differential effects of gonadotropin-releasing hormone (GnRH) pulse frequency on gonadotropin subunit and GnRH receptor messenger ribonucleic acid levels in vitro. *Endocrinology*; 138:1224-1231. 1997.
- Karacan M, Erkan H, Karabulut O, Sarikamis B, Camlibel T, Benhabib M, Clinical pregnancy rates in an IVF program. Use of the flare-up protocol after failure with long regimens of GnRH-a, *J Reprod Med* 46:485, 2001.
- Karande V, Morris R, Rinehart J, Miller C, Rao R, Gleicher N, Limited success using the “flare” protocol in poor responders in cycles with low basal follicle-stimulating hormone levels during in vitro fertilization, *Fertil Steril* 67:900, 1997.
- King JA, Millar RP: Coordinated evolution of GnRHs and their receptors. In: Parhar, IS, Sakuma Y, ed. *GnRH Neurons: Gene to Behavior*, Tokyo: Brain Shuppan;:51-77. 1997.
- King JA, Millar RP: Structure of chicken hypothalamic luteinizing hormone-releasing hormone. II. Isolation and characterization. *J Biol Chem*; 257:10729-10732. 1982.

- Klein NA, Battaglia DE, Miller PB, Branigan EF, Giudice LC, Soules MR, Ovarian follicular development and the follicular fluid hormones and growth factors in normal women of advanced reproductive age, *J Clin Endocrinol Metab* 81:1946, 1996.
- Klein NA, Harper AJ, Houmard BS, Sluss PM, Soules MR, Is the short follicular phase in older women secondary to advanced or accelerated dominant follicle development?, *J Clin Endocrinol Metab* 87:5746, 2002.
- Klein NA, Illingworth PJ, Groome NP, McNeilly AS, Battaglia AS, Soules MR Decreased inhibin B secretion is associated with the monotropic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. *J Clin Endocrinol Metab*, , 81:7:2742-2745. 1996.
- Klein NA, Soules MR: Endocrine changes of the perimenopause. *Clin Obstet Gynecol*;41:912-920.1998.
- Knauff EA, Eijkemans MJ, Lambalk CB, ten Kate-Booij MJ, Hoek A, Beerendonk CC, Laven JS, Goverde AJ, Broekmans FJ, Themmen AP, de Jong FH, Fauser BC, Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure, *J Clin Endocrinol Metab* 94:786, 2009.
- Kolibianakis E, Bourgain C, Albano C, Osmanagaoglu K, Smits J, Van Steirteghem A, Devroey P, Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up, *Fertil Steril* 78:1025, 2002.
- Kolibianakis E, Zikopoulos K, Albano C, Camus M, Tournaye H, Van Steirteghem A, Devroey P, Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI, *Reprod Biomed Online* 7:313, 2003.
- Kolibianakis E, Zikopoulos K, Camus M, Tournaye H, Van Steirteghem A, Devroey P, Modified natural cycle for IVF does not offer a realistic chance of parenthood in poor responders with high day 3 FSH levels, as a last resort prior to oocyte donation, *Hum Reprod* 19:2545, 2004.
- Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P, Relationship between LH and oestradiol in IVF cycles before GnRH antagonist initiation, *Reprod Biomed Online* 7:190, 2003.
- Kolibianakis EM, Albano C, Kahn J, Camus M, Tournaye H, Van Steirteghem AC, Devroey P, Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropinreleasing hormone antagonist cycles is associated with a reduced chance of pregnancy, *Fertil Steril* 79:873, 2003.
- Kupesic S, Kurjak A, Bjelos D, Vujisic S, Three-dimensional ultrasonographic ovarian measurements and in vitro fertilization outcome are related to age, *Fertil Steril* 79:190, 2003.
- Lasley BL, Santoro N, Randolph JF, Gold EB, Crawford S, Weiss G, McConnell DS, Sowers MF, The relationship of circulating dehydroepiandrosterone, testosterone, and estradiol to stages of the menopausal transition and ethnicity, *J Clin Endocrinol Metab* 87:3760, 2002.

- Lass A, Skull J, McVeigh E, Margara R, Winston RM, Measurement of ovarian volume by transvaginal sonography before human menopausal gonadotrophin superovulation for in-vitro fertilization can predict poor response, *Hum Reprod* 12:294, 1997.
- Lee DM, Yeoman RR, Battaglia DE, Stouffer RL, Zelinski- Wooten MB, Fanton JW, Wolf DP, Live birth after ovarian tissue transplant, *Nature* 428:137, 2004.
- Lin YH, Hwang JL, Seow KM, Huang LW, Hsieh BC, Tzeng CR, Comparison of outcome of clomiphene citrate/human menopausal gonadotropin/cetrorelix protocol and buserelin long protocol –a randomized study, *Gynecol Endocrinol* 22:297, 2006.
- Lobo RA: Treatment of the Postmenopausal Woman. Basic and Clinical Aspects. 2nd ed. Baltimore, Lippincott Williams & Wilkins, p 67. 1999.
- Loffler KA, Zarkower D, Koopman P: Etiology of ovarian failure in blepharophimosis ptosis epicanthus inversus syndrome: FOXL2 is a conserved, early-acting gene in vertebrate ovarian development. *Endocrinology*; 144:3237-3243. 2003.
- Longscope C, Franz C, Morello C, et al: Steroid and gonadotropin levels in women during the perimenopausal years. *Maturitas* ; 8:189-196. 1986.
- Loumaye E, Vankrieken L, Depreester S, Psalti I, de Cooman S, Thomas K, Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyper-stimulation for in vitro fertilization and their consequences for embryo development, *Fertil Steril* 51:105, 1989.
- Loutradi KE, Kolibianakis EM, Venetis CA, Papanikolaou EG, Pados G, Bontis I, Tarlatzis BC, Cryopreservation of human embryos by vitrification or slow freezing: a systematic review and meta-analysis, *Fertil Steril* 90:186, 2008.
- Ludwig M, Katalinic A, Banz C, Schroder AK, Loning M, Weiss JM, Diedrich K, Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study, *Hum Reprod* 17:2842, 2002.
- MacDougall MJ, Tan SL, Hall V, Balen A, Mason BA, Jacobs HS, Comparison of natural with clomiphene citrate-stimulated cycles in in vitro fertilization: a prospective, randomized trial, *Fertil Steril* 61:1052, 1994.
- Macklon NS, Stouffer RL, Giudice LC, Fauser BC, The science behind 25 years of ovarian stimulation for in vitro fertilization, *Endocr Rev* 27:170, 2006.
- MacNaughton J, Bangah M, McCloud P, Hee J, Burger HG, Age related changes in follicle stimulating hormone, luteinizing hormone, oestradiol and immunoreactive inhibin in women of reproductive age, *Clin Endocrinol* 36:339, 1992.
- Mansour R, Aboulghar M, Serour GI, Al-Inany HG, Fahmy I, Amin Y, The use of clomiphene citrate/human menopausal gonadotropins in conjunction with GnRH antagonist in an IVF/ICSI program is not a cost effective protocol, *Acta Obstet Gynecol Scand* 82:48, 2003.
- Marshall JC, Dalkin AC, Haisenleder DJ, et al: GnRH pulses-the regulators of human reproduction. *Trans Am Clin Climatol Assoc*; 104:31-46. 1993.
- Matikainen T, Ding YQ, Vergara M, Huhtaniemi I, Couzinet B, Schaison G, Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and

- agonist treatments in postmenopausal women, *J Clin Endocrinol Metab* 75:820, 1992.
- McIlveen M, Skull JD, Ledger WL, Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population, *Hum Reprod* 22:778, 2007.
- McKinlay SM, Brambilla DJ, Posner JG: The normal menopause transition. *Am J Hum Biol.*; 4:37-46. 1992.
- McLachlan RI, Robertson DM, Healy DL, de Kretser DM, Burger HG Plasma inhibin levels during gonadotropin-induced ovarian hyper stimulation for IVF: a new index of follicular function? *Lancet* 1:1233-1234. 1986.
- Messinis IE, Milingos SD, Future use of clomiphene in ovarian stimulation. Clomiphene in the 21st century, *Hum Reprod* 13:2362, 1998.
- Meyer PM, Zeger SL, Harlow SD, Sowers M, Crawford S, Luborsky JL, Janssen I, McConnell DS, Randolph JF, Weiss G, Characterizing daily urinary hormone profiles for women at midlife using functional data analysis, *Am J Epidemiol* 165:936, 2007.
- Millar R: Brain Peptides Section. In: Kastin AJ, ed. *Handbook on Biologically Active Peptides*, Burlington, MA: Elsevier;:635-644. 2005.
- Millar RP, Lu Z-L, Pawson AJ, et al: Gonadotropin-releasing hormone receptors. *Endocr Rev*; 25(2):235-275. 2004.
- Millar RP: Gonadotropin-releasing hormones and their receptors. In: Fauser BCJM, ed. *Reproductive medicine: molecular cellular and genetic fundamentals*, Lancaster: Parthenon Publishing; 2002:199-224.
- Munster K, Schmidt L, Helm P, Length and variation in the menstrual cycle—a cross-sectional study from a Danish county, *Br J Obstet Gynaecol* 99:422, 1992.
- Nagy ZP, Chang CC, Shapiro DB, Bernal DP, Elsner CW, Mitchell-Leef D, Toledo AA, Kort HI, Clinical evaluation of the efficiency of an oocyte donation program using egg cryo-banking, *Fertil Steril* 92:520, 2009.
- Nargund G, Waterstone J, Bland J, Philips Z, Parsons J, Campbell S, Cumulative conception and live birth rates in natural (unstimulated) IVF cycles, *Hum Reprod* 16:259, 2001.
- Nilsson E, Rogers N, Skinner MK, Actions of anti-Mullerian hormone on the ovarian transcriptome to inhibit primordial to primary follicle transition, *Reproduction* 134:209, 2007.
- Noyes N, Porcu E, Borini A, Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies, *Reprod Biomed Online* 18:769, 2009.
- Oktay K, Cil AP, Bang H, Efficiency of oocyte cryopreservation: a meta-analysis, *Fertil i R*, Seracchioli R, Ciotti PM, Magrini O, Flamigni C, Birth of a healthy female after intracytoplasmic sperm injection of cryopreserved human oocytes, *Fertil Steril* 68:724, 1997.
- Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R, The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg, *Hum Reprod* 13:2411, 1998.
- Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P, Frydman R, Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-

- releasing hormone (LH-RH) antagonist (cetorelix) or a depot formula of an LH-RH agonist (triptorelin), *Fertil Steril* 73:314, 2000.
- Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R, The use of GnRH antagonists in ovarian stimulation, *Hum Reprod Update* 8:279, 2002.
- Olivennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM, Safety and efficacy of a 3 mg dose of the GnRH antagonist cetorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences, *Reprod Biomed Online* 6:432, 2003.
- Ortmann O, Weiss JM, Diedrich K, Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists, *Hum Reprod* 16:608, 2001.
- Padilla SL, Dugan K, Maruschak V, Shalika S, Smith RD, Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders, *Fertil Steril* 65:796, 1996.
- Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S, Interventions for 'poor responders' to controlled ovarian hyper-stimulation (COH) in in-vitro fertilization (IVF). *Cochrane Database Syst Rev* 20:CD004379, 2010.
- Pawson AJ, Katz A, Sun YM, et al: Contrasting internalization kinetics of human and chicken gonadotropin-releasing hormone receptors mediated by C-terminal tail. *J Endocrinol* 1998; 156:R9-12.
- Pearlstone AC, Fournet N, Gambone JC, Pang SC, Buyalos RP, Ovulation induction in women age 40 and older: the importance of basal follicle-stimulating hormone level and chronological age, *Fertil Steril* 58:674, 1992.
- Pelinck MJ, Hoek A, Simons AH, Heineman MJ, Efficacy of natural cycle IVF: a review of the literature, *Hum Reprod Update* 8:129, 2002.
- Pelinck MJ, Vogel NE, Hoek A, Simons AH, Arts EG, Mochtar MH, Beemsterboer S, Hondelink MN, Heineman MJ, Cumulative pregnancy rates after three cycles of minimal stimulation IVF and results according to subfertility diagnosis: a multicentre cohort study, *Hum Reprod* 21:2375, 2006.
- Polak de Fried E, Notrica J, Rubinstein M, Marazzi A, Gomez Gonzalez M, Pregnancy after human donor oocyte cryopreservation and thawing in association with intracytoplasmic sperm injection in a patient with ovarian failure, *Fertil Steril* 69:555, 1998.
- Practice Committee of the American Society for Reproductive Medicine, ASRM Practice Committee response to Rybak and Lieman: elective self-donation of oocytes, *Fertil Steril* 92:1513, 2009.
- Quigley MM, Schmidt CL, Beauchamp PJ, Pace-Owens S, Berkowitz AS, Wolf DP, Enhanced follicular recruitment in an in vitro fertilization program: clomiphene alone versus a clomiphene/ human menopausal gonadotropin combination, *Fertil Steril* 42:25, 1984.
- Rannevik G, Jeppsson S, Johnell O, et al: A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG, and bone mineral density. *Maturitas*; 21:103-113. 1995.


- Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru- Schally AM, Schally AV, Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview, *Hum Reprod* 10:1974, 1995.
- Reynaud K, Cortvrindt R, Smits J, et al: Alterations in ovarian function of mice reduced amounts of KIT receptor. *Reproduction*; 121:229-237.2001.
- Robertson DM, Burger HG: Reproductive hormones: ageing and the perimenopause. *Acta Obstet Gynecol Scand*; 81:612. 2002.
- Rosendahl M, Loft A, Byskov AG, Ziebe S, Schmidt KT, Andersen AN, Ottosen C, Andersen CY, Biochemical pregnancy after fertilization of an oocyte aspirated from a heterotopic autotransplant of cryopreserved ovarian tissue: case report, *Hum Reprod* 21: 2006.
- Rossmannith WG, Scherbaum WA, Lauritzen C: Gonadotropin secretion during aging in postmenopausal women. *Neuroendocrinology* 1991; 54:211-218.
- Rybak EA, Lieman HJ, Egg freezing, procreative liberty, and ICSI: the double standards confronting elective self-donation of oocytes, *Fertil Steril* 92:1509, 2009.
- San Roman GA, Surrey ES, Judd HL, Kerin JF, A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization, *Fertil Steril* 58:744, 1992.
- Santoro N, Banwell T, Tortoriello D, et al: Effects of aging and gonadal failure on the hypothalamic-pituitary axis in women. *Am J Obstet Gynecol*; 178:732-741. 1998.
- Santoro N, Brown JR, Adel T, Skurnick JH, Characterization of reproductive hormonal dynamics in the perimenopause, *J Clin Endocrinol Metab* 81:1495, 1996.
- Santoro N: The menopause transition: an update. *Hum Reprod Update*; 8:155-160. 2002.
- Schwanzel-Fukuda M, Pfaff DW: Origin of luteinizing hormone-releasing hormone neurons. *Nature*; 338:161-164. 1989.
- Schwingl PJ, Hulka BS, Harlow SD: Risk factors for menopausal hot flashes. *Obstet Gynecol* 1994; 64:29.
- Scott Jr RT, Elkind-Hirsch KE, Styne-Gross A, Miller KA, Frattarelli JL, The predictive value for in vitro fertility delivery rates is greatly impacted by the method used to select the threshold between normal and elevated basal follicle-stimulating hormone, *Fertil Steril* 89:868, 2008.
- Scott Jr RT, Hofmann GE, Prognostic assessment of ovarian reserve, *Fertil Steril* 63:1, 1995.
- Scott RT, Navot D, Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction of in vitro fertilization, *Fertil Steril* 61:880, 1994.
- Seifer DB, Gardiner AC, Lambert-Messerlian G, Schneyer AL Differential secretion of dimeric inhibin in cultured luteinized granulosa cells as a function of ovarian reserve. *J Clin Endocrinol Metab* 81:7:736-739. 1996.
- Shaw JM, Oranratnachai A, Trounson AO, Fundamental cryobiology of mammalian oocytes and ovarian tissue, *Theriogenology* 53:59, 2000.
- Sherman BM, West JH, Korenman SG, The menopausal transition: analysis of LH, FSH, estradiol, and progesterone concentrations during menstrual cycles of older women, *J Clin Endocrinol Metab* 42:629, 1976.

- Silber SJ, Fresh ovarian tissue and whole ovary transplantation, *Seminars Reprod Med* 27:479, 2009.
- Silber SJ, Gosden RG, Ovarian transplantation in a series of monozygotic twins discordant for ovarian failure, *New Engl J Med* 356:1382, 2007.
- Soules MR, Sherman S, Parrott E, et al: Executive summary: Stages of Reproductive Aging Workshop (STRAW). *Fertil Steril*; 76:874-878. 2001.
- Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, Harlow SD, Randolph Jr. JF, Anti-müllerian hormone and inhibin B in the definition of ovarian aging and the menopause transition, *J Clin Endocrinol Metab* 93:3478, 2008.
- Sowers MR, Eyvazzadeh AD, McConnell D, Yosef M, Jannausch ML, Zhang D, Harlow S, Randolph Jr JF, Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition, *J Clin Endocrinol Metab* 93:3478, 2008.
- Sowers MR, Zheng H, McConnell D, Nan B, Harlow SD, Randolph Jr. JF, Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women, *J ClinEndocrinol Metab* 93:3847, 2008.
- Speroff L, Glass H, Kase NG: *Clinical Gynecologic Endocrinology and Infertility*. 6th ed. Baltimore, Lippincott Williams & Wilkins, p 116. 1999.
- Stachecki JJ, Willadsen SM, Cryopreservation of mouse oocytes using a medium with low sodium content: effect of plunge temperature, *Cryobiology* 40:4, 2000.
- Steptoe PC, Edwards RG, Birth after the reimplantation of a human embryo, *Lancet* 2:366, 1978.
- Sun YM, Flanagan CA, Illing N, et al: A chicken gonadotropin-releasing hormone receptor that confers agonist activity to mammalian antagonists. Identification of D-Lys(6) in the ligand and extracellular loop two of the receptor as determinants. *J Biol Chem* ; 276:7754-7761. 2001.
- Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW, Clinical and endocrine effects of a micro-dose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization, *Fertil Steril* 69:419, 1998.
- Surrey ES, Schoolcraft WB, Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques, *Fertil Steril* 73:667, 2000.
- Tamada T, Iwasake H: Age at natural menopause in Japanese women. *Nippon Sanka Fujinka Gakkai Zasshi*; 47:947-952. 1995.
- Tensen C, Okuzawa K, Blumenrohr M, et al: Distinct efficacies for two endogenous ligands on a single cognate gonadoliberin receptor. *Eur J Biochem* ; 243:134-140, 1997.
- The European Middle East Orgalutran Study Group, Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation, *Hum Reprod* 16:644, 2001.
- Tibilette MG, Testa G, Vegetti W, et al: The idiopathic forms of premature menopause and early menopause show the same genetic pattern. *Hum Reprod* ; 14:2731-2734. 1999.
- Trad FS, Toner M, Biggers JD, Effects of cryoprotectants and ice seeding temperature on intracellular freezing and survival of human oocytes, *Hum Reprod* 14:1569, 1999.
- Treloar AE, Boynton RE, Borghild GB, Brown BW, Variation of the human menstrual cycle through reproductive life, *Int J Fertil* 12:77, 1967.

- Treloar AE, Menstrual cyclicity and the pre-menopause, *Maturitas* 3:249, 1981.
- Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y, Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women, *Hum Reprod* 22:1837, 2007.
- Ulloa-Aguirre A, Stanislaus D, Arora V, et al: The third intracellular loop of the rat gonadotropin-releasing hormone receptor couples the receptor to Gs- and G(q/11)-mediated signal transduction pathways: evidence from loop fragment transfection in GGH3 cells. *Endocrinology* 1998; 139:2472-2478.
- Utian WH: The International Menopause Society. Menopause-related terminology definitions. *Climacteric*; 2:284-286. 1999.
- van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, Fauser BJ, Themmen AP, te Velde ER, Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study, *Fertil Steril* 83:979, 2005.
- van Rooij IA, Tonkelaar I, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, Themmen AP, te Velde ER, Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition, *Menopause* 11:601, 2004.
- Verberg MF, Macklon NS, Nargund G, Frydman R, Devroey P, Broekmans FJ, Fauser BC, Mild ovarian stimulation for IVF, *Hum Reprod Update* 15:13, 2009.
- Visser JA, De Jong FH, Laven JS, Themmen AP, Anti-müllerian hormone: a new marker for ovarian function, *Reproduction* 131:1, 2006.
- Vrecl M, Anderson L, Hanyaloglu A, et al: Agonist-induced endocytosis and recycling of the gonadotropin-releasing hormone receptor: effect of beta-arrestin on internalization kinetics. *Mol Endocrinol*; 12:1818-1829. 1998.
- Wang L, Bogerd J, Choi HS, et al: Three distinct types of gonadotropin-releasing hormone receptor characterized in the bullfrog. *Proc Natl Acad Sci U S A* 2001; 98:361-366.
- Weel AE, Utterlinden AG, Westendorp IC, et al: Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. *J Clin Endocr Metab*; 84:3146-3150. 1999.
- Weghofer A, Margreiter M, Bassim S, Sevelde U, Beilhack E, Feichtinger W, Minimal stimulation using recombinant follicle stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age, *Fertil Steril* 81:1002, 2004.
- Weigert M, Krischker U, Pohl M, Poschalko G, Kindermann C, Feichtinger W, Comparison of stimulation with clomiphene citrate in combination with recombinant follicle-stimulating hormone and recombinant luteinizing hormone to stimulation with a gonadotropin-releasing hormone agonist protocol: a prospective, randomized study, *Fertil Steril* 78:34, 2002.
- Welt CK, McNicholl DJ, Taylor AE, Hall JE, Female reproductive aging is marked by decreased secretion of dimeric inhibin, *J Clin Endocrinol Metab* 84:105, 1999.
- Whiteman MK, Staropoli CA, Benedict JC, et al: Risk factors for hot flashes in midlife women. *J Women's Health*; 12:459-472. 2003.
- WHO Scientific Group: Research on Menopause in the 1990s. Report of a WHO Scientific Group. WHO Technical Report Series 866. Geneva, World Health Organization, 1996.

- Williams SC, Gibbons WE, Muasher SJ, Oehninger S, Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist, *Fertil Steril* 78:1068, 2002.
- Yong PY, Baird DT, Thong KJ, McNeilly AS, Anderson RA, Prospective analysis of the relationships between the ovarian follicle cohort and basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle number at different stages of the normal menstrual cycle and after pituitary down-regulation, *Hum Reprod* 18:35, 2003.
- Zapantis G, Santoro N: Ovarian ageing and the menopause transition. *Best Pract Res Clin Obstet Gynaecol* 2002; 16:263-276. *Psychiatry*; 60:29-36. 2003.
- Zumoff B, Straw GW, Miller LK, et al: Twenty-four hour mean plasma testosterone concentration declines with age in normal premenopausal women. *J Clin Endocrinol Metab*; 80:1429-1430. 1995

IntechOpen



Artificial Insemination in Farm Animals

Edited by Dr. Milad Manafi

ISBN 978-953-307-312-5

Hard cover, 300 pages

Publisher InTech

Published online 21, June, 2011

Published in print edition June, 2011

Artificial insemination is used instead of natural mating for reproduction purposes and its chief priority is that the desirable characteristics of a bull or other male livestock animal can be passed on more quickly and to more progeny than if that animal is mated with females in a natural fashion. This book contains under one cover 16 chapters of concise, up-to-date information on artificial insemination in buffalos, ewes, pigs, swine, sheep, goats, pigs and dogs. Cryopreservation effect on sperm quality and fertility, new method and diagnostic test in semen analysis, management factors affecting fertility after cervical insemination, factors of non-infectious nature affecting the fertility, fatty acids effects on reproductive performance of ruminants, particularities of bovine artificial insemination, sperm preparation techniques and reproductive endocrinology diseases are described. This book will explain the advantages and disadvantages of using AI, the various methodologies used in different species, and how AI can be used to improve reproductive efficiency in farm animals.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Zoe Roupa, Greta Wozniak, Konstantinos Tsipras and Penelope Sotiropoulou (2011). Reproductive Endocrinology Diseases: Hormone Replacement and Therapy for Peri/Menopause, Artificial Insemination in Farm Animals, Dr. Milad Manafi (Ed.), ISBN: 978-953-307-312-5, InTech, Available from: <http://www.intechopen.com/books/artificial-insemination-in-farm-animals/reproductive-endocrinology-diseases-hormone-replacement-and-therapy-for-peri-menopause>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike-3.0 License](https://creativecommons.org/licenses/by-nc-sa/3.0/), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited and derivative works building on this content are distributed under the same license.

IntechOpen

IntechOpen